Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Coformulated quavonlimab and pembrolizumab (pembro) in combination with lenvatinib (lenva) as first-line (1L) therapy for patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 2 KEYSTEP-004 study.
Lorenza Rimassa, Daneng Li, Masafumi Ikeda, Mark Yarchoan, Baek‐Yeol Ryoo, Thibaud Kössler, Ho-Yeong Lim, Mariusz Kwiatkowski, Ting‐Tsung Chang, Jee Hyun Kim, Andrea Casadei‐Gardini, Masatoshi Kudo, Zhenggang Ren, Marı́a Varela, Josep M. Llovet, Yayan Zhang, Ken Hatogai, Abby B. Siegel, Ann‐Lii Cheng (2024). Coformulated quavonlimab and pembrolizumab (pembro) in combination with lenvatinib (lenva) as first-line (1L) therapy for patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 2 KEYSTEP-004 study.. Journal of Clinical Oncology, 42(3_suppl), pp. 484-484, DOI: 10.1200/jco.2024.42.3_suppl.484.
Article351 days agoAtezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial
Daneng Li, Han Chong Toh, Philippe Merle, Kaoru Tsuchiya, Sairy Hernandez, Wendy Verret, Alan Nicholas, Masatoshi Kudo (2022). Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial. , 11(6), DOI: https://doi.org/10.1159/000525671.
Article13 days agoAbstract CT009: IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)
Richard S. Finn, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae‐You Kim, Masatoshi Kudo, Ho Yeong Lim, В. В. Бредер, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Yin‐Hsun Feng, Wendy Verret, Alan Nicholas, Lindong Li, Ning Ma, Andrew X. Zhu, Ann‐Lii Cheng (2021). Abstract CT009: IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC). , 81(13_Supplement), DOI: https://doi.org/10.1158/1538-7445.am2021-ct009.
Article13 days agoUpdated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae‐You Kim, Ho Yeong Lim, Masatoshi Kudo, В. В. Бредер, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Wendy Verret, Ning Ma, Alan Nicholas, Yifan Wang, Lindong Li, Andrew X. Zhu, Richard S. Finn (2021). Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. , 76(4), DOI: https://doi.org/10.1016/j.jhep.2021.11.030.
Article13 days agoUpdated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae‐You Kim, Ho Yeong Lim, Masatoshi Kudo, В. В. Бредер, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Wendy Verret, Ning Ma, Alan Nicholas, Yifan Wang, Lindong Li, Andrew X. Zhu, Richard S. Finn, Masatoshi Kudo (2021). Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. , 76(4), DOI: https://doi.org/10.1016/j.jhep.2021.11.030.
Article13 days ago